GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Beijing Strong Biotechnologies Inc (SZSE:300406) » Definitions » Return-on-Tangible-Equity

Beijing Strong Biotechnologies (SZSE:300406) Return-on-Tangible-Equity : 23.49% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Beijing Strong Biotechnologies Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Beijing Strong Biotechnologies's annualized net income for the quarter that ended in Mar. 2024 was ¥483 Mil. Beijing Strong Biotechnologies's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ¥2,054 Mil. Therefore, Beijing Strong Biotechnologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 23.49%.

The historical rank and industry rank for Beijing Strong Biotechnologies's Return-on-Tangible-Equity or its related term are showing as below:

SZSE:300406' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.16   Med: 22.68   Max: 31.43
Current: 28.56

During the past 13 years, Beijing Strong Biotechnologies's highest Return-on-Tangible-Equity was 31.43%. The lowest was 7.16%. And the median was 22.68%.

SZSE:300406's Return-on-Tangible-Equity is ranked better than
78.06% of 196 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.175 vs SZSE:300406: 28.56

Beijing Strong Biotechnologies Return-on-Tangible-Equity Historical Data

The historical data trend for Beijing Strong Biotechnologies's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Strong Biotechnologies Return-on-Tangible-Equity Chart

Beijing Strong Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.42 7.16 31.43 29.25 29.72

Beijing Strong Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.95 30.88 28.97 31.78 23.49

Competitive Comparison of Beijing Strong Biotechnologies's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Strong Biotechnologies's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Beijing Strong Biotechnologies's Return-on-Tangible-Equity falls into.



Beijing Strong Biotechnologies Return-on-Tangible-Equity Calculation

Beijing Strong Biotechnologies's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=523.743/( (1532.824+1991.558 )/ 2 )
=523.743/1762.191
=29.72 %

Beijing Strong Biotechnologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=482.592/( (1991.558+2116.772)/ 2 )
=482.592/2054.165
=23.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Beijing Strong Biotechnologies  (SZSE:300406) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Beijing Strong Biotechnologies Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Strong Biotechnologies (SZSE:300406) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Hua Yuan Dong Lu, 5th Floor, Kuang Yi Building, Haidian District, Beijing, CHN, 100191
Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.
Executives
Shuang He Executives
Luo Ai Ping Director
Directors, executives
Liu Wei Executives
Zhou Ming Executives
Zhuang Xian Min Directors, executives
Zhang Yi Executives
Liu Xi Directors, executives
Sun Xiao Lin Director
Yu Jian Ping Executives

Beijing Strong Biotechnologies (SZSE:300406) Headlines

No Headlines